Altimmune, Inc.(ALT)

$2.97—

Chart

Altimmune, Inc.(ALT)

NASDAQ

$2.97—

Chart Studio

ALT(ALT)

ALT

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.14

Nov 5, 2026 · Reports before open

Revenue Estimate

$1,750

Analyst Sentiment

Wall St. Consensus

Buy

15 analysts·Moderate coverage

Score

12 Buy (80%)3 Hold (20%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1280%

Hold

320%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.50

-15.8%

Consensus

$6.25

+110.4%

Bull

$10.00

+236.7%

12-Month Target Range15 analysts

$2.50$6.25$10.00

Current $2.97Consensus

Current Price

$2.97

Upside to Consensus

$3.28

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+1372209.33%

EPS—

FY2028

Rev+265.76%

EPS—

FY2029

Rev-63.66%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$1,875	$26M	$94M	$34M	$156M
Low	$1,875	$26M	$94M	$34M	$156M
High	$1,875	$26M	$94M	$34M	$156M
EBITDA Avg	$-1,125	$-15M	$-56M	$-21M	$-94M
Low	$-1,125	$-15M	$-56M	$-21M	$-94M
High	$-1,125	$-15M	$-56M	$-21M	$-94M
EBIT Avg	$-1,125	$-15M	$-56M	$-21M	$-94M
Low	$-1,125	$-15M	$-56M	$-21M	$-94M
High	$-1,125	$-15M	$-56M	$-21M	$-94M
Net Income Avg	$-56M	$-57M	$-59M	$-61M	$-62M
Low	$-70M	$-72M	$-84M	$-61M	$-62M
High	$-43M	$-41M	$-34M	$-61M	$-62M
EPS Avg	$-0.60	$-0.66	$-0.68	$-0.69	$-0.71
Low	$-0.79	$-0.82	$-0.95	$-0.69	$-0.71
High	$-0.49	$-0.46	$-0.38	$-0.69	$-0.71
Analysts (Rev / EPS)	6 / 7	6 / 7	8 / 7	6 / 2	6 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$1,750	$1,750	$18M	—	—	—	—	—
Low	$1,750	$1,750	$18M	—	—	—	—	—
High	$1,750	$1,750	$18M	—	—	—	—	—
EBITDA Avg	$-1,050	$-1,050	$-11M	—	—	—	—	—
Low	$-1,050	$-1,050	$-11M	—	—	—	—	—
High	$-1,050	$-1,050	$-11M	—	—	—	—	—
EBIT Avg	$-1,050	$-1,050	$-11M	—	—	—	—	—
Low	$-1,050	$-1,050	$-11M	—	—	—	—	—
High	$-1,050	$-1,050	$-11M	—	—	—	—	—
Net Income Avg	$-26M	$-30M	$-35M	$-36M	$-38M	$-40M	$-36M	$-35M
Low	$-34M	$-33M	$-35M	$-36M	$-38M	$-40M	$-36M	$-35M
High	$-18M	$-26M	$-35M	$-36M	$-38M	$-40M	$-36M	$-35M
EPS Avg	$-0.14	$-0.16	$-0.19	$-0.20	$-0.20	$-0.21	$-0.19	$-0.19
Low	$-0.18	$-0.18	$-0.19	$-0.20	$-0.20	$-0.21	$-0.19	$-0.19
High	$-0.10	$-0.14	$-0.19	$-0.20	$-0.20	$-0.21	$-0.19	$-0.19
Analysts (Rev / EPS)	10 / 5	9 / 6	9 / 2	— / 2	— / 2	— / 2	— / 5	— / 5

Earnings Surprises

Recent Analyst Actions

Jun 22, 2026Leerink Partners

Altimmune initiated with an Outperform at Leerink

Target:$10.00

+232.8%from $3.00

Apr 24, 2026Goldman Sachs

Altimmune upgraded to Neutral from Sell at Goldman Sachs

Target:$2.50

-13.5%from $2.89

Jan 27, 2026Barclays

Altimmune initiated with an Overweight at Barclays

Target:$20.00

+223.6%from $6.18

Apr 2, 2024H.C. Wainwright

Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report

Target:$12.00

+17.3%from $10.23

Dec 1, 2022Goldman Sachs

Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

Target:$20.00

+101.0%from $9.95

Nov 11, 2022JMP Securities

JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26

Target:$26.00

+133.8%from $11.12

Aug 31, 2022Jefferies

Jefferies Maintains Buy on Altimmune, Raises Price Target to $35

Target:$35.00

+58.5%from $22.08

Aug 30, 2022Piper Sandler

Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler

Target:$25.00

+32.0%from $18.94

Aug 17, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50

Target:$50.00

+183.1%from $17.66

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance